Loading
HLA-B (HLA class I histocompatibility antigen, B alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Oesophageal cancer, Head and neck squamous cell carcinoma and 3 more.
Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumour-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.52 (direct and indirect evidence; datatypes literature 0.86, animal model 0.48, genetic association 0.00, somatic mutation 0.80). IntOGen calls it a driver in 6 cohorts (0 activating, 6 loss-of-function), covering Cervical Squamous Cell Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Oesophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Malignant Lymphoma.
In plain words · HLA-B (HLA class I histocompatibility antigen, B alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Oesophageal cancer, Head and neck squamous cell carcinoma and 3 more.
HLA-B (HLA class I histocompatibility antigen, B alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Oesophageal cancer, Head and neck squamous cell carcinoma and 3 more.
Antigen-presenting major histocompatibility complex class I (MHCI) molecule.
No product in this corpus aims at HLA-B yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA HLA-B: RNA tissue enhanced (lymphoid tissue 2,350 nTPM); high antibody staining in 24 normal tissues; highest cancer staining liver cancer (9 of 12 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Cervical cancer, Oesophageal cancer, Head and neck squamous cell carcinoma, Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P01889; CIViC gene HLA-B; IntOGen HLA-B; Human Protein Atlas HLA-B tissue; Open Targets ENSG00000234745 associations
First described 1979. Earliest sequence paper UniProt cites for the protein: Orr H.T. et al, Biochemistry, 1979, "Complete amino acid sequence of a papain-solubilized human histocompatibility antigen, HLA-B7. 2. Sequence determination and search for homologies". Source.
Sources: HGNC HGNC:4932 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P01889 (protein name, function text, keywords and locations (REST API)); CIViC gene HLA-B (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000234745 (association with cancer (MONDO_0004992) 0.52; (GraphQL API, CC0)); IntOGen HLA-B (driver in 6 cohorts (Act 0, LoF 6); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumour-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity. Both the peptide and the MHC molecule are recognised by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells. Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via constitutive proteasome and IFNG-induced immunoproteasome. Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9. Location: Cell membrane; Endoplasmic reticulum membrane (UniProt). Locus 6p21.33 (HGNC).
RNA: tissue enhanced (lymphoid tissue 2,350 nTPM), detected in many normal tissues.
Medium: Adrenal gland, Cervix, Gallbladder, Salivary gland, Vagina.
Medium only: testis cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"HLA-B" OR ABSTRACT:"HLA-B" OR TITLE:"major histocompatibility complex, class I, B" OR ABSTRACT:"major histocompatibility complex, class I, B" OR TITLE:"HLA class I histocompatibility antigen, B alpha chain" OR ABSTRACT:"HLA class I histocompatibility antigen, B alpha chain") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLA-B, not a curated reading list.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Cervical cancer, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.